[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,85,0,25,[9,45,73,98,131,158,182,206,232,258,293,320,346,374,401,421,456,477,507,534,557,580,595,610,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100582532","adjuvant-chemotherapy-for-high-malignant-prostate-cancer-100582532",false,"NCT06864533","Adjuvant Chemotherapy for High Malignant Prostate Cancer","Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial","PKUFH-GS5","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer diagnosed by biopsy or surgery with a Gleason score of 9-10 (GG grade 5) or containing Gleason 5 components.\n2. No evidence of distant metastasis confirmed by imaging.\n3. Expected to receive standard radical treatment or postoperative radiotherapy.\n4. Estimated survival time greater than 12 months.\n5. Aged ≥ 18 years.\n6. Karnofsky Performance Status (KPS) ≥ 80.\n7. Adequate blood count: white blood cell ≥ 3.5 × 10\\^9\u002FL, neutrophils ≥ 1.5 × 10\\^9\u002FL, platelets ≥ 100.0 × 10\\^\n\nExclusion Criteria:\n\n1. History of malignant tumors (except those cured for more than 5 years).\n2. Previous abdominal radiation therapy.\n3. Weight loss \\> 10% within the past 6 months.\n4. Pre-existing or concomitant bleeding disorders.\n5. Active infections.\n6. Significant cardiovascular disease (e.g., controlled hypertension, unstable angina, NYHA class ≥ II congestive heart failure, unstable symptomatic arrhythmias, or ≥ II peripheral vascular disease) or any condition deemed intolerable to chemotherapy by the oncology department.","MALE","18 Years","80 Years",{"count":22,"type":23},315,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.",[28,29,30,31],"Prostate Cancer","Radiation Therapy","Chemotherapy","Gleason Score","RECRUITING","2026-08-18",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2019-09-01",{"date":40,"type":23},"2031-09-01",{"name":42,"class":43},"Peking University First Hospital","OTHER",3,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100575132","phase-2-assessment-of-adebelizumab-combined-with-chemotherapy-in-concurrent-radiotherapy-versus-sequential-radiotherapy-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-100575132","NCT06768307","Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.","Inclusion Criteria:\n\n* Age ≥18 years, no gender restrictions;\n* Confirmed pathological diagnosis of extensive-stage small cell lung cancer (ES-SCLC), defined as disease extending beyond one hemithorax, including malignant pleural and pericardial effusions or hematogenous metastases (according to the Veterans Administration Lung Cancer Study Group, VALG staging); stage IV (any T, any N, M1a\u002Fb\u002Fc) according to the AJCC (8th edition), or T3-4 due to multiple pulmonary nodules or tumor\u002Fnodule size too large to be included in a tolerable radiation therapy plan;\n* Participants have not received systemic treatment for extensive-stage SCLC;\n* No more than 5 lesions (including metastatic foci), with at least one measurable lesion (according to RECIST v1.1);\n* ECOG performance status score of 0-2;\n* Life expectancy ≥3 months;\n* Consented and signed the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures;\n* Normal major organ function, meeting the following criteria (without symptomatic treatment within 14 days): a) Hematology:\n\nHemoglobin (Hb) ≥90g\u002FL; Platelet (PLT) ≥100×10\\^9\u002FL; Neutrophil count (ANC) ≥1.5×10\\^9\u002FL; White blood cell count (WBC) ≥3.0×10\\^9\u002FL;\n\nLymphocyte ≥0.5×10\\^9\u002FL; b) Biochemistry:\n\nAlanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) ≤ 2.5×ULN; For those with liver metastasis, ALT, AST≤5 ULN; For those with liver or bone metastasis: ALP ≤5 ULN; Total serum bilirubin (TBIL) ≤1.5×ULN (for Gilbert's syndrome participants ≤3×ULN); Albumin (ALB) ≥3 g\u002FdL;\n\nRenal function: Serum creatinine ≤1.5 x ULN or creatinine clearance rate (CrCl) ≥50mL\u002Fminute (using Cockcroft\u002FGault formula); c) Coagulation:\n\nActivated partial thromboplastin time (APTT), International Normalized Ratio (INR), Prothrombin Time (PT) ≤1.5×ULN; d) Others: Lipase ≤1.5 x ULN. Participants with lipase \\>1.5 x ULN without clinical or radiological evidence of pancreatitis can be included; e) Doppler echocardiography: Left ventricular ejection fraction (LVEF) ≥50%;\n\n* Female participants of childbearing potential must have a negative serum HCG test within 72 hours before the first dose, not breastfeeding, and must use a medically recognized contraceptive method (such as intrauterine devices, birth control pills, or condoms) during the study treatment and for 2 months after the last dose of Adebrelimab or 6 months after the last dose of Carboplatin\u002FEtoposide (whichever is longer); male participants with partners of childbearing potential must be surgically sterilized or agree to use highly effective contraception during the trial and for 2 months after the last dose of Adebrelimab or 3 months after the last dose of Carboplatin\u002FEtoposide (whichever is longer), and no sperm donation during the study.\n\nExclusion Criteria:\n\n* Participants who have previously received any T-cell co-stimulation or immune checkpoint therapy, including but not limited to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1\u002F2 inhibitors, CD137 agonists, or other T-cell targeted drugs.\n* Participants who have previously received chemoradiotherapy for limited-stage SCLC;\n* Participants with clinically symptomatic central nervous system metastases (such as brain, spinal cord), or leptomeningeal metastases; participants with active or new CNS metastases found on imaging during the screening period are not included. (Asymptomatic untreated CNS metastases with a lesion size \\\u003C1cm are allowed to be included);\n* Participants with multiple liver metastases (isolated liver metastasis participants with metastasis \\\u003C2cm can be included)\n* Participants with spinal cord compression;\n* Participants with active autoimmune diseases requiring systemic treatment (such as disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years before the first dose, or with a history of autoimmune diseases and expected recurrence. Replacement therapies (such as thyroid hormone, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are not considered systemic treatment;\n* Diagnosed with immune deficiency or receiving systemic glucocorticoid treatment or any other form of immunosuppressive therapy within 14 days before the first dose; the use of physiological doses of glucocorticoids (≤10 mg\u002Fday of prednisone or equivalent) is allowed;\n* Participants who have had arterial\u002Fvenous thrombotic events within 6 months before the first dose, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral embolism, etc.), deep vein thrombosis, and pulmonary embolism;\n* Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia (such as cryptogenic organizing pneumonia), drug-induced pneumonia, or idiopathic pneumonia, or evidence of active pneumonia on chest computed tomography (CT) at screening (participants with active tuberculosis are not included);\n* Participants who have undergone major surgical treatment or significant traumatic injury within 28 days before the first dose;\n* Participants who have received or plan to receive preventive vaccines or live-attenuated vaccines within 4 weeks before the first dose;\n* Participants who have received other trial medications or participated in another interventional clinical study within 4 weeks before signing the ICF;\n* Participants with other malignancies that require active treatment within 5 years (except for those with a \\>90% 5-year survival rate such as fully treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, localized prostate cancer after radical surgery, localized bladder cancer, ductal carcinoma in situ after radical surgery, or in situ breast cancer);\n* Participants with any severe and\u002For uncontrolled diseases, including: a) Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90mmHg) participants; history of hypertensive crisis or hypertensive encephalopathy; b) Uncontrolled cardiac clinical symptoms or diseases such as ≥grade 2 myocardial ischemia or myocardial infarction, uncontrollable arrhythmias (including men QTc ≥450ms, women QTc ≥470ms), and ≥grade 2 congestive heart failure (New York Heart Association, NYHA classification), unstable angina, myocardial infarction within 24 weeks, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; c) Active or uncontrolled severe infections (≥CTC AE grade 2 infections), including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia, unexplained fever \\>38.5℃ before the first dose. d) Liver cirrhosis, active hepatitis\\*; \\*Active hepatitis - Hepatitis B reference: HBsAg positive, exceeding the upper limit of normal (1000 copies\u002Fml or 500 IU\u002Fml); participants with past Hepatitis B virus (HBV) infection or cured HBV infection (defined as the presence of hepatitis B core antibody \\[HBcAb\\] and absence of HbsAg, and normal HBV DNA values detected during the screening period can be included; \\*Hepatitis C reference: HCV antibody positive, and HCV viral load exceeds the upper limit of normal\u002FHCV RNA or HCV Ab indicates acute or chronic infection; e) HIV positive or known Acquired Immune Deficiency Syndrome (AIDS); f) Urine routine suggests urinary protein ≥++, and confirmed 24-hour urinary protein quantification \\>1.0 g;\n* Participants with clinically symptomatic third-space fluid accumulation, such as pericardial effusion, pleural effusion, and abdominal effusion requiring repeated drainage (such as once a month or more frequently) that cannot be controlled by tapping or other treatments;\n* Participants whose adverse events (except for alopecia) caused by previous treatments have not recovered to ≤CTCAE grade 1; other toxicities caused by previous antitumor treatments that are expected to be unresolved and have long-term persistent sequelae, such as neurotoxicity caused by platinum-based treatments, are allowed to be included;\n* Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* Known history of drug abuse that cannot be quit, mental disorders, alcoholism, drug abuse, or substance abuse;\n* Known allergy to study drugs or excipients, known severe allergic reactions to any monoclonal antibody;\n* As judged by the investigator, there are factors that seriously endanger the safety of the participants or other factors that may lead to the forced termination.","ALL",{"count":54,"type":23},60,"INTERVENTIONAL",[57],"PHASE2","Immunotherapy combined with chemotherapy has emerged as the standard of care for patients with extensive-stage small cell lung cancer (ES-SCLC). The incorporation of thoracic radiotherapy can enhance treatment efficacy. Currently, the main types of research investigating immunotherapy combined with thoracic radiotherapy for untreated ES-SCLC are concurrent radiotherapy and sequential radiotherapy. The aim of this study is to evaluate the efficacy of adebelizumab in combination with chemotherapy, when administered concurrently with radiotherapy versus sequentially with radiotherapy, as a first-line treatment for ES-SCLC.",[60,61,30,62],"SCLC, Extensive Stage","Immunotherapy","Radiotherapy","2026-08-13",{"date":65,"type":36},"2026-08-17",{"date":67,"type":36},"2025-01-07",{"date":69,"type":23},"2028-01-31",{"name":71,"class":43},"Peking University Cancer Hospital & Institute",1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":80,"targetDuration":4,"studyType":55,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100651340","phase-3-aromatherapy-combined-with-standard-antiemetic-therapy-vs-standard-therapy-alone-for-prevention-of-cinv-in-breast-cancer-patients-receiving-highly-emetogenic-chemotherapy-100651340","NCT07761325","Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of CINV in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy","A Phase III Randomized Controlled Trial of Aromatherapy Combined With Standard Antiemetic Therapy vs Standard Therapy Alone for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Breast Cancer Patients Receiving Highly Emetogenic Chemotherapy","Inclusion Criteria:\n\n* Histopathologically confirmed breast cancer (aged 18-80 years, inclusive).\n* Scheduled to receive or currently receiving intravenous chemotherapy, with at least 2 planned cycles.\n* Planned use of guideline-recommended triple antiemetic therapy (5-HT3 receptor antagonist + NK-1 receptor antagonist + dexamethasone).\n* ECOG performance status ≤ 2 and life expectancy ≥ 3 months.\n* Chemotherapy regimen classified as highly emetogenic risk according to CSCO, NCCN, or MASCC\u002FESMO antiemetic guidelines.\n* Able to understand the study procedures, voluntarily participate, and provide written informed consent.\n\nExclusion Criteria:\n\n* History of allergy to essential oils.\n* History of vestibular dysfunction or intestinal obstruction.\n* Major cardiovascular or cerebrovascular event within the past 12 months (e.g., unstable angina, myocardial infarction, cerebral hemorrhage, cerebral infarction; asymptomatic lacunar infarction not requiring treatment is allowed).\n* Pregnancy, lactation, or possibility of pregnancy without willingness to use contraception.\n* History or current diagnosis of significant neurological or psychiatric disorders, including epilepsy or dementia.\n* Poor compliance anticipated, or any other condition that the investigator considers inappropriate for participation.",{"count":81,"type":23},374,[83],"PHASE3","This phase III, multicenter, randomized, open-label trial evaluates whether aromatherapy plus standard antiemetic therapy improves complete response (CR) of CINV compared with standard therapy alone in breast cancer patients receiving highly emetogenic chemotherapy (HEC). Despite guideline-recommended triple prophylaxis (5-HT3 antagonist, NK-1 antagonist, dexamethasone), 30-50% of patients still develop delayed CINV. Aromatherapy with lemon, lavender, and peppermint essential oils may provide additive benefit through olfactory-limbic and vagal pathways, but phase III evidence is lacking. 374 patients (aged 18-80) scheduled for at least two HEC cycles will be randomized 1:1, stratified by prior CINV. On chemo day, aromatherapy starts 30 min before and continues until 2 h after chemotherapy; on days 2-5, inhalation is at least 2 h daily.Primary endpoint: complete response (no vomiting, no rescue antiemetic) over 0-120 h. Key secondary endpoints: acute and delayed CR rates, complete\u002Ftotal control rates, time to treatment failure, quality of life (FLIE), anxiety, depression, sleep quality, and safety. Exploratory: plasma GDF15 dynamics and predictive value.",[86,87,30,88],"Breast Cancer","Aromatherapy","CINV","NOT_YET_RECRUITING","2026-08-10",{"date":92,"type":36},"2026-08-12",{"date":33,"type":23},{"date":95,"type":23},"2030-08-30",{"name":97,"class":43},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":25,"phases":4,"briefSummary":108,"conditions":109,"keywords":118,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":72},"100568904","cognitive-impact-associated-with-surgery-for-gastric-or-esophageal-cancer-100568904","NCT06687291","Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer","CASE","Inclusion Criteria:\n\n* Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery.\n* Age ≥18 at the time for inclusion.\n* Participate on a voluntary basis and can (for any reason) end its participation during the study.\n* Capable of giving informed consent.\n\nExclusion Criteria:\n\n* Patients with preoperative cognitive dysfunction such as dementia.\n* Patients who are inoperable due to metastases.\n* Patients unable to communicate due to severely impaired hearing and\u002For - seeing.\n* Patients with ongoing drug and\u002For alcohol abuse.\n* Patients who cannot give informed consent.",{"count":106,"type":23},130,"6 Months","The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery. Secondary objectives are to investigate the relationship between POD, preoperative depression, frailty, quality of life, malnutrition and sarcopenia.\n\nParticipants identified with POD will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview, in order to understand the participant's experience of postoperative delirium.\n\nThe main objective aims to answer:\n\nWhat is the incidence of POD after gastroesophageal cancer surgery.",[110,111,112,113,114,115,116,30,117],"Gastroesophageal Cancer (GC)","Postoperative Delirium (POD)","Quality of Life (QOL)","Frailty","Malnutrition","Sarcopenia","Chemobrain","Depression",[119,120,113,121,122,114,115,116,30],"postoperative delirium","gastroesophageal cancer","Quality of life","Preoperative depression",{"date":124,"type":36},"2026-08-11",{"date":126,"type":36},"2025-02-13",{"date":128,"type":23},"2028-11-11",{"name":130,"class":43},"Karolinska Institutet",{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":55,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":72},"100650016","phase-2-targeted-induction-therapy-for-stage-iii-unresectable-egfr-mutant-positive-nsclc-100650016","NCT07742332","Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC","Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC: a Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;\n* At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or\u002Fand EBUS;\n* No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);\n* With the feasibility to receive radical surgery ;\n* Good lung function that could tolerate surgical treatment;\n* Minimum age: 18 years;\n* At least one measurable tumor foci (the longest diameter measured by CT shall be \\> 10 mm);\n* Other major organs shall function well (liver, kidney, blood system, etc.):\n* ECOG PS score shall be 0-1;\n* The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;\n* The patient shall sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;\n* The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \\[≥ Grade II specified by New York Heart Association (NYHA)\\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;\n* The patient is a carrier of HIV;\n* The patient has had or is currently suffering from interstitial lung disease;\n* The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;\n* The patient is allergic to befotertinib or its any excipients;\n* The patient is allergic to bevacizumab or its any excipients;\n* The patient is allergic to platinum-based double chemotherapy or its any excipients;\n* The female patient is in pregnancy or lactation period;\n* There are any conditions under which the investigator considers the patient is not suitable to be enrolled.",{"count":139,"type":23},160,[57],"The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.",[143,144,145,62,30],"EGFR","NSCLC (Non-small Cell Lung Cancer)","Locally Advanced Non-Small Cell Lung Cancer",[30,143,147,148,145],"NSCLC (non-small cell lung cancer)","radiotherapy","2026-07-29",{"date":151,"type":36},"2026-08-03",{"date":153,"type":36},"2025-11-25",{"date":155,"type":23},"2032-11-25",{"name":157,"class":43},"Peng Zhang",{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":55,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100649739","phase-2-iparomlimab-and-tuvonralimab-ql1706-plus-lenvatinib-and-chemotherapy-for-extrapulmonary-neuroendocrine-carcinoma-100649739","NCT07738159","Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma","A Prospective, Randomized, Controlled Clinical Trial of Iparomlimab and Tuvonralimab Injection (QL1706) Plus Lenvatinib and Chemotherapy as First-Line Treatment for Extrapulmonary Neuroendocrine Carcinoma","Inclusion Criteria:\n\n1. Histologically and\u002For cytologically confirmed locally advanced unresectable or metastatic extrapulmonary neuroendocrine carcinoma. Eligible primary sites include the gastrointestinal tract, pancreas, biliary tract, and other extrapulmonary organs. Neuroendocrine carcinoma of the digestive system must be diagnosed according to the 2019 World Health Organization Classification of Tumours of the Digestive System.\n2. Age ≥18 years, with no restriction on sex.\n3. Life expectancy of at least 12 weeks.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.\n5. Patients must not have received prior first-line systemic anticancer therapy for advanced or metastatic disease. Patients who previously received adjuvant therapy following curative surgery are eligible, provided that disease recurrence occurred more than 6 months after completion of adjuvant therapy.\n6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).\n7. No severe complications related to the primary tumor, including perforation, obstruction, or major bleeding that cannot be adequately controlled with medical treatment.\n8. Adequate organ function, as demonstrated by the following laboratory results obtained within 7 days before enrollment. Patients must not have received blood transfusion, granulocyte colony-stimulating factor (G-CSF), or other supportive treatment affecting the relevant laboratory parameters within 14 days before the first dose of study treatment: Hemoglobin ≥90 g\u002FL; Platelet count ≥75 × 10⁹\u002FL; White blood cell count ≥3.0 × 10⁹\u002FL; Absolute neutrophil count ≥1.5 × 10⁹\u002FL; Total bilirubin ≤1.5 × the upper limit of normal (ULN); Serum creatinine ≤1.5 × ULN; Alanine aminotransferase and aspartate aminotransferase ≤2.5 × ULN, or ≤5 × ULN in participants with liver metastases.\n9. Participants with active hepatitis B virus or hepatitis C virus infection must have received antiviral therapy for at least 14 days before the first dose of study treatment. Hepatitis B virus DNA must be ≤500 IU\u002FmL or ≤2,500 copies\u002FmL, and hepatitis C virus RNA must be below the lower limit of detection of the applicable assay. Such participants must be willing to continue effective antiviral treatment throughout the study.\n10. Voluntary participation in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Histologically confirmed neuroendocrine tumor, mixed adenoneuroendocrine carcinoma, or other non-neuroendocrine carcinoma pathological types.\n2. History of another malignancy with a disease-free interval of less than 5 years, except for adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, or a gastrointestinal tumor confirmed to have been cured by endoscopic mucosal resection.\n3. Uncontrolled hypertension despite medical treatment, defined as systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mmHg.\n4. Urine protein ≥2+ on routine urinalysis or 24-hour urinary protein ≥1 g.\n5. Major surgery within 4 weeks before enrollment, excluding diagnostic biopsy, or an incompletely healed surgical wound.\n6. Severe gastrointestinal disorders that may affect drug absorption, including but not limited to peptic ulcer, ulcerative colitis, active gastrointestinal bleeding, gastrointestinal obstruction, or severe diarrhea.\n7. A history of severe bleeding within the previous 3 months, defined as a single bleeding episode of \\>30 mL; hemoptysis within the previous 1 month, defined as a single episode of \\>5 mL; or a thromboembolic event within the previous 12 months, including pulmonary embolism or cerebral infarction.\n8. Severe cardiovascular disease, including but not limited to acute myocardial infarction, unstable angina, heart failure, ventricular arrhythmia requiring medical treatment, left ventricular ejection fraction \\\u003C50%, or New York Heart Association cardiac functional class II or higher.\n9. Corrected QT interval (QTc) \\>480 ms on electrocardiography.\n10. Active autoimmune disease, a history of autoimmune disease with a risk of recurrence, or another condition requiring immunosuppressive treatment, such as prior organ transplantation. Participants with type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, or skin disorders not requiring systemic treatment, such as vitiligo, psoriasis, or alopecia, may be enrolled.\n11. A history of interstitial lung disease or noninfectious pneumonitis that is symptomatic, or a previous pulmonary condition that may interfere with the evaluation or management of study treatment-related pulmonary toxicity.\n12. Active pulmonary tuberculosis within 1 year before the first dose of study treatment. Patients with a history of active pulmonary tuberculosis more than 1 year before the first dose must undergo careful evaluation, including sputum smear examination, T-SPOT.TB testing, erythrocyte sedimentation rate testing, and chest computed tomography. Such participants may be enrolled only if there is no evidence of active pulmonary tuberculosis.\n13. A history of chronic persistent diarrhea or the presence of complete intestinal obstruction.\n14. Requirement for systemic treatment with corticosteroids at a prednisone-equivalent dose of \\>10 mg\u002Fday or other immunosuppressive agents within 14 days before the first dose of study treatment. Inhaled or topical corticosteroids and adrenal replacement therapy at a prednisone-equivalent dose of ≤10 mg\u002Fday are permitted in the absence of active autoimmune disease. Short-term corticosteroid use for ≤7 days is permitted for prophylaxis, such as prevention of contrast-media allergy, or for the treatment of non-autoimmune conditions, such as delayed hypersensitivity caused by contact allergens.\n15. Prior treatment with any antibody or drug targeting a T-cell co-regulatory protein or immune checkpoint, including but not limited to anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-OX-40, anti-CD137, anti-TIM-3, or anti-LAG-3 therapies.\n16. Immunodeficiency disorder or human immunodeficiency virus infection.\n17. Severe medical or surgical comorbidities that impair organ function, or an acute infection associated with a body temperature \\>38°C, which, in the investigator's judgment, would make the patient unsuitable for the study.\n18. Leptomeningeal metastases or symptomatic brain metastases.\n19. Pregnant or breastfeeding women, or patients of reproductive potential, including male patients and women who have been postmenopausal for less than 1 year, who are unwilling to use effective contraception.\n20. A history of allergy or hypersensitivity to any component of the study treatments.\n21. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.",{"count":166,"type":23},92,[57],"The aim of this prospective, randomized, controlled clinical trial is to evaluate the efficacy and safety of iparomlimab and tuvonralimab injection (QL1706) plus lenvatinib and etoposide-based platinum chemotherapy, consisting of etoposide plus cisplatin or carboplatin, compared with etoposide-based platinum chemotherapy alone as first-line treatment for patients with extrapulmonary neuroendocrine carcinoma. Potential predictive biomarkers will also be explored through analyses of tumor tissue, peripheral blood, and relevant clinical and pathological data.",[170,171,172,30],"Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","QL1706","Lenvatinib","2026-07-28",{"date":175,"type":36},"2026-07-31",{"date":177,"type":23},"2026-08-01",{"date":179,"type":23},"2030-09-01",{"name":181,"class":43},"West China Hospital",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":55,"phases":192,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":54},"100430810","alnd-vs-art-in-positive-sentinel-node-after-neoadjuvant-therapy-in-breast-cancer-100430810","NCT04889924","ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer","Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Breast Cancer Patients With Positive Sentinel Node After Neoadjuvant Therapy: A Multicenter Randomized Study","ADARNAT","Inclusion Criteria:\n\n* T1-T4 N0\u002F T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment\n* Post-CT SLN with ≤2 macrometastasis\u002Fmicrometastasis or ITCs\n* Post-CT axillary response by ultrasound or MRI\n* Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.\n\nExclusion Criteria:\n\n* cN2\n* ypN0\n* History of breast surgery for ipsilateral cancer in the last 10 years\n* History of other cancer in the last 5 years, except squamous carcinoma of the skin.",{"count":191,"type":23},820,[193],"NA","In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphadenectomy.\n\nThe primary endpoint is to evaluate wether axillary radiotherapy (ART) presents a lower risk of lymphedema with respect to lymphadenectomy (ALND) in patients with breast cancer who, after neoadjuvant systemic treatment (NST), present the sentinel node affected. Likewise, we will evaluate recurrences and overall survival in both groups. Finally, we will analyze the quality of life of these patients.",[86,30,196,197,198],"Sentinel Lymph Node","Axillary Lymph Nodes Dissection","Radiotherapy Side Effect",{"date":149,"type":36},{"date":201,"type":36},"2021-06-11",{"date":203,"type":23},"2028-12-31",{"name":205,"class":43},"Hospital Universitari de Bellvitge",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":212,"sex":213,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":55,"phases":216,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":72},"100649089","the-effect-of-a-virtual-reality-based-mindfulness-intervention-on-anxiety-comfort-sleep-and-fatigue-in-breast-cancer-patients-undergoing-chemotherapy-100649089","NCT07731477","The Effect of a Virtual Reality-Based Mindfulness Intervention on Anxiety, Comfort, Sleep, and Fatigue in Breast Cancer Patients Undergoing Chemotherapy","Inclusion Criteria:\n\nNewly diagnosed with breast cancer, Female and aged 18 years or older, Diagnosed with stage II or III breast cancer, Scheduled to receive chemotherapy for breast cancer for the first time in the adjuvant or neoadjuvant setting, using either the CA regimen \\[C: cyclophosphamide; A: doxorubicin (Adriamycin)\\] or the TC regimen \\[T: docetaxel; C: cyclophosphamide\\], with or without paclitaxel, trastuzumab, docetaxel, or carboplatin, Scheduled to receive chemotherapy but have not yet started treatment, Have a Beck Depression Inventory (BDI) score of ≤30, have no physician-diagnosed psychiatric disorder according to the DSM-5 diagnostic criteria, and are not receiving treatment for a psychiatric disorder (Appendix 8), Have completed at least primary school education, Voluntarily agree to participate in the study.\n\nExclusion Criteria:\n\nPresence of metastasis, History of seizures, Presence of vertigo, Presence of motion sickness with a tendency toward nausea and vomiting, Communication difficulties, including hearing, visual, or speech impairments, Unwillingness to participate in the study. Withdrawal Criteria\n\nParticipants will be withdrawn from the study if:\n\nThey discontinue the treatment protocol at any stage, Their treatment protocol is changed, They no longer wish to continue participating in the study.",true,"FEMALE",{"count":215,"type":23},50,[193],"Breast cancer is a public health issue with a high incidence among women worldwide, and its prevalence continues to increase each year. A breast cancer diagnosis brings significant physical, emotional, social, economic, and occupational changes. Chemotherapy, one of the most commonly used treatment modalities in cancer therapy, causes various physical and emotional symptoms while treating the disease. However, it is well known that these symptoms induced by chemotherapy can be prevented or alleviated through effective treatment and nursing interventions.\n\nRecently, virtual reality (VR) and mindfulness-based interventions have been reported as effective tools and methods for managing the physical and psychological symptoms experienced by cancer patients.\n\nThe present study aims to evaluate the effect of a VR-integrated mindfulness-based intervention on anxiety, comfort, sleep, and fatigue levels among women newly diagnosed with breast cancer, both before and during chemotherapy treatment. The study is designed as a randomized controlled trial (RCT).\n\nThe study population will consist of individuals diagnosed with breast cancer at the Oncology Outpatient Clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between May 2025 and December 2026. The study sample will include female breast cancer patients who are scheduled to receive adjuvant chemotherapy, meet the inclusion criteria, and volunteer to participate in the study.\n\nAccording to the power analysis (with a 30% additional error margin), a total of 50 participants will be included - 25 in the intervention group and 25 in the control group.\n\nThe data will be collected using the following instruments: Patient Information Form, Beck Depression Inventory, Cancer Fatigue Scale, General Comfort Questionnaire-Short Form, State Anxiety Inventory, Jenkins Sleep Scale, and the Mindfulness-Based Self-Efficacy Scale.\n\nIt is expected that, as a result of this study, compared to the control group, participants in the intervention group who receive the VR-Mindfulness intervention during breast cancer treatment will demonstrate reduced levels of fatigue and anxiety and improved comfort and sleep quality.",[86,30],[220,221,222,223],"Breast cancer","chemotherapy","Mindfulness","Virtual Reality","2026-07-22",{"date":173,"type":36},{"date":227,"type":36},"2025-10-01",{"date":229,"type":23},"2026-09-30",{"name":231,"class":43},"Hacettepe University",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":55,"phases":241,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":72},"100647881","effect-of-ai-assisted-expressive-writing-on-anxiety-emotional-distress-and-quality-of-life-among-patients-receiving-chemotherapy-100647881","NCT07713381","Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy","The Effect of AI-Assisted Expressive Writing on Anxiety, Emotional Distress, and Quality of Life Among Patients Receiving Chemotherapy: A Mixed-Methods Study","Inclusion Criteria:\n\n* Adult patients aged 18 years and above.\n* Diagnosed with any type of cancer and currently receiving chemotherapy treatment.\n* Able to read and write Arabic.\n* Able to communicate and express thoughts and feelings.\n* Have access to a smartphone, tablet, or computer with internet connectivity.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Diagnosed with severe psychiatric disorders (e.g., psychosis or schizophrenia).\n* Having cognitive impairment that interferes with understanding or communication.\n* Currently receiving structured psychological therapy during the study period.\n* Unable to complete the study questionnaires or intervention sessions.\n* Refusal to participate or withdrawal from the study at any time.",{"count":240,"type":23},100,[193],"This study aims to evaluate the effect of an AI-assisted expressive writing intervention on anxiety, emotional distress, and quality of life among patients receiving chemotherapy. A mixed-methods, interventional research design will be employed. Participants will be assigned to either a study group receiving the AI-assisted expressive writing program in addition to routine care or a control group receiving routine care only. Quantitative data will be collected using the Depression Anxiety Stress Scale-21 (DASS-21) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Qualitative data will be obtained through semi-structured interviews to explore participants' experiences with the intervention. The findings are expected to provide evidence regarding the effectiveness of AI-assisted expressive writing as a supportive strategy for improving psychological well-being and quality of life among patients undergoing chemotherapy.",[244,30,245],"Cancer","Anxiety",[247,248,30],"Artificial Intelligence","AI-Assisted Expressive Writing","2026-07-16",{"date":251,"type":36},"2026-07-20",{"date":253,"type":23},"2026-07-10",{"date":255,"type":23},"2026-09-10",{"name":257,"class":43},"Alexandria University",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":213,"minAge":19,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":268,"conditions":269,"keywords":282,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":4},"100645943","quality-of-life-of-patients-who-have-undergone-bilateral-mastectomy-100645943","NCT07699913","Quality of Life of Patients Who Have Undergone Bilateral Mastectomy","Psychological Experience, Quality of Life, and Patient Satisfaction Following Bilateral Breast Reconstruction After Prophylactic or Therapeutic Mastectomy, Using the BREAST-Q Questionnaire.","RM BREAST Q","Inclusion Criteria:\n\n* Female sex\n* Age ≥ 18 years\n* Bilateral mastectomy\n* Breast reconstruction between January 1, 2015, and January 1, 2026\n* No objection to the study\n\nExclusion Criteria:\n\n* Individual under guardianship or curatorship, or deprived of liberty\n* Reconstruction not completed by January 1, 2026.",{"count":267,"type":23},115,"The investigators therefore aim to determine whether the type of mastectomy (preventive in a high-risk patient or therapeutic in a patient with a history of cancer), as well as the timing (immediate or delayed) and type of breast reconstruction, influence the quality of life and satisfaction of patients who have undergone bilateral mastectomy. The goal of this observational study is thus to measure and compare the quality of life of patients who have undergone bilateral mastectomy using the BREAST-Q questionnaire.",[270,271,272,273,274,275,276,30,62,277,278,279,280,281],"Surgery Date","Age","BMI","Height","Weight","Smoking Status","Hormone Therapy","Postoperative Complications","Type of Reconstruction (Flap or Implant)","Timing of Reconstruction","Type of Mastectomy (Prophylactic or Therapeutic)","BRCA Mutation",[283,284,285],"Comparative","observational","retrospective","2026-07-13",{"date":288,"type":36},"2026-07-15",{"date":253,"type":23},{"date":35,"type":23},{"name":292,"class":43},"University Hospital, Grenoble",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":52,"minAge":300,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":55,"phases":303,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":319},"100606424","resilience-enhancement-using-electronic-frailty-index-directed-care-pathway-100606424","NCT07175376","Resilience Enhancement Using Electronic Frailty Index-Directed Care Pathway","Resilience Enhancement Utilizing an Electronic Frailty Index-Directed Care Pathway for Older Adults Receiving Chemotherapy (RESILIENCE-e): A Prospective Single-Arm Interventional Study","Inclusion Criteria:\n\nPatients with cancer:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥ 65 years at the time of enrollment.\n* Planned to initiate an outpatient chemotherapy regimen (including myelosuppressive biologic\u002Fimmune therapies) for cancer treatment (any type or stage), either as an initial therapy or as a new line of therapy, with curative or palliative intent.\n* eFI pre-frail or frail status (available in EHR; defined as eFI \\> 0.10) within 30 days before enrollment.\n* Ability to read and understand the English language\n\nProviders:\n\n* Treating medical oncologist of at least one patient participant who enrolled on to the study and completed baseline assessment.\n\nExclusion Criteria:\n\nPatients:\n\n* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study per the enrolling investigator.\n* Chemotherapy planned at a facility outside the Atrium Health system.\n* Currently receiving chemotherapy (defined as planned to continue an on-going treatment rather than starting a new regimen).","65 Years",{"count":302,"type":23},32,[193],"The study purpose is to gain a better understanding of the needs of adults aged 65 and older while they are receiving chemotherapy by measuring their resilience and tailor care plans based on their individual needs.",[244,306,30],"Frail",[244,308,309],"Frailty Index","eFI score","2026-07-01",{"date":312,"type":36},"2026-07-02",{"date":314,"type":36},"2026-03-16",{"date":316,"type":23},"2027-05",{"name":318,"class":43},"Wake Forest University Health Sciences",2,{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":213,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":55,"phases":330,"briefSummary":331,"conditions":332,"keywords":336,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":72},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034","NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.",{"count":329,"type":23},108,[193],"This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[223,333,86,30,334,245,335],"Guided Imagery","Pain","Fatigue",[337],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","2026-06-27",{"date":340,"type":36},"2026-06-30",{"date":310,"type":23},{"date":343,"type":23},"2027-03",{"name":345,"class":43},"Thoalfokar Mohammed Al-Obaidi",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":55,"phases":355,"briefSummary":356,"conditions":357,"keywords":361,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":72},"100644315","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-early-stage-cancer-100644315","NCT07663396","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Early-stage Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of early-stage cancer(I-III stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. Non small cell lung cancer or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal; Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with advanced cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":354,"type":23},278,[193],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with early stage cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[358,30,359,360],"Electroacupuncture","Peripheral Neuropathy","Early Stage Cancer",[362,30,363,364],"electroacupuncture","Peripheral neuropathy","early stage cancer","2026-06-17",{"date":367,"type":36},"2026-06-23",{"date":369,"type":23},"2026-05-25",{"date":371,"type":23},"2029-07-31",{"name":373,"class":43},"Affiliated Hospital of Qinghai University",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":55,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":72},"100619043","phase-2-intestinal-low-dose-radiotherapy-plus-immunochemotherapy-for-conversion-of-borderline-resectableunresectable-esophageal-squamous-cell-carcinoma-100619043","NCT07339488","Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","ILDR-03","Inclusion Criteria:\n\n1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.\n2. Age ≥18 years and ≤75 years; both sexes are eligible.\n3. ECOG performance status score of 0-1.\n4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.\n5. Thoracic esophageal cancer.\n6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.\n7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.\n8. Baseline laboratory requirements (within 7 days prior to enrollment):\n\n   Hematology:\n   1. Hb≥90 g\u002FL (no transfusion within 14 days)\n   2. NEUT ≥1.5×10⁹\u002FL\n   3. PLT ≥100×10⁹\u002FL\n   4. WBC≥3×10⁹\u002FL\n\n   Biochemistry:\n   1. ALT and AST≤2.5×ULN\n   2. TBIL≤1.5×ULN\n   3. SCr≤1.5×ULN; or CrCl≥60 mL\u002Fmin Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3\u002FFT4 levels should also be considered; eligible if FT3\u002FFT4 are normal) Echocardiography: LVEF≥50%\n9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.\n10. No psychological, familial, social, or geographical factors that may impair protocol adherence.\n11. Other parameters meet general clinical trial enrollment criteria.\n12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases other than supraclavicular lymph node metastases.\n2. Presence or high risk of esophageal perforation.\n3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.\n4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.\n5. Patients with a history of thoracoabdominal\u002Fpelvic radiotherapy within 6 months prior to enrollment.\n6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).\n7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.\n8. Respiratory depression, airway obstruction, or tissue hypoxia.\n9. Severe cardiac disease (i.e., NYHA functional class II or higher).\n10. Markedly abnormal liver or kidney function (i.e., indicators \\>3 times the upper limit of normal).\n11. Active hepatitis B, hepatitis C, HIV, or syphilis.\n12. Active brain disease or central nervous system\u002Fmeningeal metastases with significant symptoms, or impaired decision-making capacity.\n13. Hypersensitivity to drugs included in the trial.\n14. Drug and\u002For alcohol abuse.\n15. Pregnant or lactating women.\n16. Concurrent participation in another therapeutic clinical trial.\n17. Major surgical procedure within 30 days prior to enrollment.\n18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.","75 Years",{"count":384,"type":23},43,[57],"Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.\n\nCurrent conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.\n\nRetrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.\n\nBased on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR\u002FUR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR\u002FUR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg\u002Fm² on day 1), cisplatin (75 mg\u002Fm² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.",[388,389,390,391,30,62,392],"Borderline Resectable Carcinoma","Unresectable Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Immune Checkpoint Inhibitor","Tislelizumab",{"date":394,"type":36},"2026-06-18",{"date":396,"type":36},"2025-12-05",{"date":398,"type":23},"2028-11-01",{"name":400,"class":43},"Chuangzhen Chen",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":55,"phases":410,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":420,"locationsCount":72},"100642496","electroacupuncture-for-preventing-chemotherapy-induced-peripheral-neuropathy-in-patients-with-advanced-cancer-100642496","NCT07644533","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer","Electroacupuncture for Preventing Chemotherapy-Induced Peripheral Neuropathy in Patients With Advanced Cancer: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Pathological and imaging examinations confirmed the diagnosis of advanced cancer(IV stage), including: breast cancer, gastric cancer, intestinal cancer, non-small cell lung cancer or ovarian cancer;\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1.\n* Scheduled to receive chemotherapy containing a taxane, utidelone, or oxaliplatin, with no significant pre-existing neurological symptoms prior to chemotherapy. Specific regimens include: Colorectal cancer: Oxaliplatin-containing regimen. Gastric cancer: Oxaliplatin-containing or taxane-containing regimen. Breast cancer: Taxane-containing or utidelone-containing regimen. NSCLC or Ovarian cancer: Taxane-containing regimen.\n* No history of acupuncture treatment within one month prior to study initiation.\n* Adequate major organ function, meeting the following laboratory criteria: Hematology: Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelet count ≥ 100 × 10\\^9\u002FL; White blood cell count 3.5 - 9.5 × 10\\^9\u002FL; Hemoglobin ≥ 100 g\u002FL. Hepatic Function: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Aspartate aminotransferase and alanine aminotransferase ≤ 3 × ULN; Serum bilirubin concentration \\\u003C 1.5 mg\u002FdL; Serum albumin \\> 2.5 g\u002FdL. Renal Function: Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance ≥ 50 mL\u002Fmin (using the Cockcroft-Gault formula). Coagulation: International normalized ratio ≤ 1.5, AND activated partial thromboplastin time ≤ 1.5 × ULN.\n* Willing to receive acupuncture intervention and undergo subsequent follow-up assessments.\n* Voluntarily agree to participate in the study and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with early-stage cancer.\n* Pre-existing peripheral neuropathy prior to the initiation of chemotherapy.\n* Severe impairment of major organ function, rendering the patient unable to tolerate standard-dose chemotherapy.\n* Presence of active skin infection or other conditions unsuitable for acupuncture treatment.\n* Coexisting underlying diseases associated with peripheral neuropathy, such as diabetes mellitus, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy.\n* Current use of medications for neuropathic pain (e.g., gabapentin, pregabalin).\n* Pregnant or lactating patients.\n* Presence of dermatological conditions, as assessed by the clinician, that may interfere with the study procedures or outcomes.\n* Patients with active brain metastases.\n* Patients with a history of implanted cardiac pacemakers or defibrillators, or a history of epilepsy.",{"count":409,"type":23},264,[193],"This randomized controlled clinical trial aims to clarify the clinical efficacy and safety of electroacupuncture combined with thumbtack needle for the prevention of chemotherapy-induced peripheral neuropathy(CIPN), and to provide high-level evidence-based medicine for the prevention of CIPN in patients with advanced cancer. At the same time, the effects of electroacupuncture on the median nerve, tibial nerve, sural nerve sensory conduction velocity and sensory nerve action potential, as well as on the median nerve and tibial nerve motor conduction velocity will be analyzed.",[358,30,413,359],"Advanced Cancer",[30,413,363,358],"2026-06-10",{"date":417,"type":36},"2026-06-12",{"date":369,"type":23},{"date":371,"type":23},{"name":373,"class":43},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":55,"phases":430,"briefSummary":431,"conditions":432,"keywords":441,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":72},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":429,"type":23},400,[57,83],"This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[433,434,435,62,30,436,198,437,438,439,440],"Rectal Cancer","Total Neoadjuvant Treatment","Neoadjuvant Therapy","Organ Preservation","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[442,434,443,62,30,438,436,198,444,445,335,446,439],"Rectal cancer","Neoadjuvant therapy","Chemotherapy side effects","Quality of Lifte","Postoperative complications","2026-05-06",{"date":449,"type":36},"2026-05-11",{"date":451,"type":36},"2025-01-06",{"date":453,"type":23},"2029-12-27",{"name":455,"class":43},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":55,"phases":466,"briefSummary":467,"conditions":468,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":44},"100511615","phase-3-ic-plus-low-dose-radiation-plus-cadonilimab-in-lanpc-100511615","NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy, radiotherapy or immunotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 9g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Distant metastases;\n* Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Pregnancy or lactation;\n* Have uncontrolled cardiovascular disease;\n* Severe complication, eg, uncontrolled hypertension;\n* Mental disorder;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts.","70 Years",{"count":465,"type":23},380,[83],"This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.",[469,391,62,30],"Nasopharyngeal Carcinoma",{"date":449,"type":36},{"date":472,"type":36},"2024-01-10",{"date":474,"type":23},"2029-12",{"name":476,"class":43},"Sun Yat-sen University",{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":55,"phases":486,"briefSummary":487,"conditions":488,"keywords":492,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":72},"100636937","phase-2-sotagliflozin-as-prevention-of-anthracycline-related-cardiotoxicity-100636937","NCT07572175","Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity","SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)","SPARTACUS","Inclusion Criteria\n\n* Patients ≥ 18 years\n* Newly diagnosed lymphoma\n* Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg\u002Fm2)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-3\n\nExclusion Criteria\n\n* Prior anthracycline treatment\n* Previous malignancy requiring any chemotherapy or radiotherapy\n* Previous treatment with SGLT2i (eg due to T2DM) or SGLT1\u002F2i\n* Previous heart failure (HF patients should already be on SGLT2i as per guidelines)\n* LVEF\\\u003C40% (even in the absence of HF):\n* Pregnancy or breastfeeding\n* Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)",{"count":54,"type":23},[57],"This project aims to determine the benefits of the dual SGLT1\u002F2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.",[489,490,30,491],"Anthracycline-induced Cardiotoxicity","Lymphoma","Cardiotoxicity",[493,494,495,496,497],"anthracycline","left ventricular dysfunction","cardiotoxicity","SGLT inhibitors","prevention","2026-04-30",{"date":500,"type":36},"2026-05-07",{"date":502,"type":23},"2026-07",{"date":504,"type":23},"2029-10",{"name":506,"class":43},"Icahn School of Medicine at Mount Sinai",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":516,"conditions":517,"keywords":522,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":532,"locationsCount":72},"100627052","measuring-fluid-buildup-in-cancer-patients-100627052","NCT07443618","Measuring Fluid Buildup in Cancer Patients","Monitoring of Oedema in Cancer Patients - A Pilot Study","Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving radiotherapy due to breast cancer within the last 6 months\n* Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital\n* Age ≥ 18 years\n* Visible lymphoedema in at least one upper extremity\n\nInclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving chemotherapy due to cancer within the last 2 months\n* Hospitalised in the Oncology Ward at Aalborg University Hospital\n* Estimated length of hospital stay of at least 6 days\n* Age ≥ 18 years\n* Visible peripheral oedema in at least one lower extremity\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women\n* Amputated limb(s)\n* Pacemaker or implanted cardioverter-defibrillator due to risk of interference from the electrical signal\n* Metallic prostheses due to risk of interference with the device signal\n* Inability to lie still for the duration of the measurement interval (minimum 2 minutes at a time)\n* Inability to stand on a scale, i.e. permanently bedridden.\n* Inability to cooperate with urine collection\n* Receiving dialysis\n* Terminal illness",{"count":515,"type":23},46,"The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include:\n\n* Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients)\n* Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized)\n\nParticipants will:\n\n* Have measurements taken using bioelectrical impedance\n* Provide blood samples and 24-hour urine collection\n* Weight monitorering\n* Complete diet and fluid registration (inclusive enteral and parenteral)\n* Have clinical palpatory and measurement assessment of oedema.",[244,518,519,520,30,62,521],"Oedema","Bioelectrical Impedance","Lymphoedema","Fluid Balance",[523,524,525],"Localized oedema in cancer","Bioelectrical impedance","Post radiation lymphoedema","2026-04-28",{"date":528,"type":36},"2026-04-29",{"date":530,"type":36},"2026-02-01",{"date":175,"type":23},{"name":533,"class":43},"Jens Rikardt Andersen",{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":12,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":55,"phases":543,"briefSummary":544,"conditions":545,"keywords":546,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":553,"completionDateStruct":554,"leadSponsor":555,"locationsCount":4},"100619596","phase-2-comparing-of-sesame-oil-nitroglycerin-ointment-and-aloe-vera-gel-100619596","NCT07346677","Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel","Comparing of Sesame Oil, Nitroglycerin Ointment, and Aloe Vera Gel on Prevention of Phlebitis Induced by Chemotherapy","Inclusion Criteria:\n\n* adult conscious patients of both gender.\n* Patients receiving chemotherapy antimetabolites (5-fluorouracil).\n* Patients receiving chemotherapy alkylating agents (Cisplatin).\n* Patients receiving chemotherapy through peripheral IV cannula.\n* Patients breast cancer colon cancer.\n\nExclusion Criteria:\n\n* Phlebitis has already appeared at the IV infusion site.\n* Patients using port or central venous catheters to administer chemotherapy. - Patient radiation therapy, immunity therapy and palliative therapy\n* Patients receiving chemotherapy (antitumor antibiotics, plant alkaloids).",{"count":542,"type":23},190,[57],"compare the effectiveness sesame oil, aloe Vera gel, and nitroglycerin ointment prevention of phlebitis.",[244,30],[547,548,549,550],"sesame oil","aloe Vera gel","nitroglycerin ointment","phlebitis","2026-04-27",{"date":526,"type":36},{"date":449,"type":23},{"date":251,"type":23},{"name":556,"class":43},"University of Basrah",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":564,"targetDuration":4,"studyType":55,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":72},"100636193","phase-2-randomized-trial-of-plasma-ctdna-methylation-guided-adjuvant-therapy-in-t4n0-and-low-risk-stage-iii-colorectal-cancer-100636193","NCT07562503","Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","CLEAR-03","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of sex;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of \\>3 months;\n3. Histologically confirmed postoperative pTNM stage high-risk stage II colorectal cancer;\n4. Positive ctDNA status at 1 month after surgery;\n5. Expected survival of \\>12 months;\n6. Ability to understand and willingness to sign a written informed consent form (personally or via a legally authorized representative\u002Fguardian), indicating that the subject understands the study objectives and required procedures and agrees to participate.\n\nExclusion Criteria:\n\n1. Receipt of neoadjuvant therapy prior to surgery;\n2. Blood transfusion during surgery or within 2 weeks prior to surgery;\n3. Pregnant or breastfeeding women, or individuals of reproductive potential who are not using adequate contraception;\n4. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer;\n5. Uncontrolled primary brain tumors or central nervous system metastases, or presence of significant intracranial hypertension or neuropsychiatric symptoms;\n6. Presence of severe or uncontrolled comorbidities, including but not limited to:Severe cardiac disease that remains unstable despite treatment, including myocardial infarction, congestive heart failure, unstable angina, symptomatic pericardial effusion, or unstable arrhythmia within 6 months prior to enrollment; Clearly diagnosed neurological or psychiatric disorders, including dementia or seizure disorders;Severe or uncontrolled infections;Active disseminated intravascular coagulation (DIC) or significant bleeding tendency;Significant impairment of major organ function;\n7. Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in this study.",{"count":565,"type":23},340,[57],"The patient (T4N0 or low-risk stage III) will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 3 months) or the intervention group (FOLFOX\u002FCAPOX for 6 months or FOLFOX\u002FCAPOX for 3 months followed by FOLFIRI\u002FCAPIRI for 3 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months after surgery for dynamic monitoring of plasma ctDNA.",[569,570,30],"ctDNA","Colorectal Cancer","2026-04-26",{"date":573,"type":36},"2026-05-01",{"date":575,"type":36},"2024-11-01",{"date":577,"type":23},"2027-12-31",{"name":579,"class":43},"Fudan University",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":585,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":586,"targetDuration":4,"studyType":55,"phases":587,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":594,"locationsCount":72},"100636192","phase-2-a-randomized-controlled-trial-of-plasma-ctdna-methylation-guided-adjuvant-chemotherapy-decision-making-in-high-risk-stage-iii-t4n-or-t1-3n2-colorectal-cancer-100636192","NCT07562490","A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","CLEAR-04",{"count":240,"type":23},[57],"Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX\u002FCAPOX for 6 months) or the intervention group (FOLFOX\u002FCAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months postoperatively for dynamic monitoring of plasma ctDNA.",[569,30,570],{"date":573,"type":36},{"date":592,"type":36},"2025-04-01",{"date":577,"type":23},{"name":579,"class":43},{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":600,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":601,"targetDuration":4,"studyType":55,"phases":602,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":609,"locationsCount":72},"100636209","phase-2-randomized-study-of-plasma-ctdna-methylation-to-guide-adjuvant-chemotherapy-decisions-in-high-risk-t3n0-colorectal-cancer-100636209","NCT07562711","Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","CLEAR-02",{"count":565,"type":23},[57],"This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery. It aims to investigate the impact of different adjuvant chemotherapy regimens on ctDNA clearance rates and their prognostic significance. By using postoperative ctDNA status to identify patients at high risk of recurrence, the study seeks to implement intensified chemotherapy strategies (treatment escalation) at an early stage, thereby improving ctDNA clearance and ultimately enhancing patient outcomes",[569,30,570],"2026-04-25",{"date":573,"type":36},{"date":575,"type":36},{"date":577,"type":23},{"name":579,"class":43},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":20,"enrollmentInfo":618,"targetDuration":4,"studyType":55,"phases":620,"briefSummary":621,"conditions":622,"keywords":626,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":633,"locationsCount":72},"100636153","phase-2-tislelizumab-plus-chemotherapy-and-bace-for-unresectable-nsclc-100636153","NCT07561983","Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC","Tislelizumab Combined With Intravenous Chemotherapy and Bronchial Artery Chemoembolization as Conversion Therapy for Unresectable Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Phase II Trial (BEACON-Lung)","BEACON-Lung","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)\n* Newly diagnosed, previously untreated stage IIIA-IIIB NSCLC according to the 9th edition TNM staging system\n* Initially unresectable disease as determined by multidisciplinary team (MDT) assessment\n* At least 1 measurable intrapulmonary lesion according to RECIST version 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Forced expiratory volume in the first second (FEV1) \\> 1.0 L and \\> 40% of predicted normal value\n* Estimated life expectancy of at least 3 months\n* Adequate organ function\n* Willingness to provide tumor tissue for pathology, molecular testing, and PD-L1 assessment before enrollment\n* Women of childbearing potential must have a negative pregnancy test within 72 hours before the first dose and agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Men with partners of childbearing potential must agree to use effective contraception during the study and for 3 months after the last dose of tislelizumab\n* Ability to understand and willingness to sign a written informed consent form\n\nExclusion Criteria:\n\n* Prior local therapy for NSCLC, including radiotherapy or interventional therapy\n* Known positive driver genomic alterations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and MET exon 14 skipping alterations\n* Distant organ metastasis\n* History of another malignancy within the past 5 years\n* Active autoimmune disease or history of autoimmune disease requiring systemic treatment\n* Known allergy to any study drug or excipient\n* Interstitial lung disease, non-infectious pneumonitis, chronic obstructive pulmonary disease, or other uncontrolled systemic diseases judged to interfere with study treatment\n* Severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral therapy, including active tuberculosis\n* Major surgery requiring general anesthesia within 4 weeks before first dose\n* Any medical condition, alcohol or drug abuse, or dependence that may interfere with study treatment, interpretation of results, or increase treatment risk\n* Participation in another interventional therapeutic clinical study\n* Psychiatric illness or history of psychotropic drug abuse that may compromise study participation\n* Any condition judged by the investigator to make the patient unsuitable for the study",{"count":619,"type":23},39,[57],"The goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NSCLC). The main questions it aims to answer are:\n\n* What is the 1-year event-free survival (EFS) rate with this treatment?\n* Can this treatment improve tumor response and the chance of curative-intent resection?\n* What adverse events occur during treatment?\n\nParticipants will receive tislelizumab, intravenous chemotherapy, and BACE for up to 4 cycles. Tumor response and resectability will be evaluated by imaging and multidisciplinary team (MDT) assessment every 2 cycles. Participants who become resectable may undergo surgery followed by postoperative treatment per protocol. Participants who remain unresectable after 4 cycles will receive guideline-recommended chemoradiotherapy followed by tislelizumab consolidation. Regular follow-up will be performed for efficacy and safety assessment.",[623,392,30,624,625],"Unresectable Stage III Non-small Cell Lung Cancer","Chemoembolization, Therapeutic","Conversion Therapy",[627,392,30,628,625],"Unresectable Non-Small Cell Lung Cancer","Bronchial Artery Chemoembolization","2026-04-24",{"date":573,"type":36},{"date":573,"type":23},{"date":203,"type":23},{"name":634,"class":43},"Sichuan Cancer Hospital and Research Institute",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":52,"minAge":19,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":644,"conditions":645,"keywords":648,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":72},"100635499","chemotherapy-induced-hearing-loss-and-health-inequality-100635499","NCT07553481","Chemotherapy-Induced Hearing Loss and Health Inequality","CANHEAR","Inclusion Criteria:\n\n* Patients receiving platinum-based chemotherapy drugs\n* Living and treated within North West England\n* Able to complete an online hearing and cognitive test\n* Fluent in English\n\nExclusion Criteria:\n\n* Following cancer types: brain tumour\u002Fmetastasis, head + neck, skin cancers around the ear, and adenoid cystic carcinoma of the auditory cortex\n* World Health Organisation performance status score of 3 or more\n* Stage 4 cancer\n* History of childhood deafness\n* Current or recent ear infections\n* Cochlear implant user\n* Known neurological impairment (e.g., stroke, traumatic brain injury, dementia)\n* Patients who look capacity to consent or complete study tasks",{"count":643,"type":23},172,"This project aims to understand how platinum-based chemotherapy affects hearing function in cancer patients from different socioeconomic backgrounds in the North West of England. Platinum-based chemotherapy drugs, such as cisplatin, are ototoxic, meaning that they cause permanent damage to the hair cells of the ear, resulting in hearing loss. Patients from more deprived backgrounds face additional risk factors to their hearing health, including limited healthcare access, greater occupational noise exposure, and poorer overall health, making them more vulnerable to hearing loss.\n\nThis is especially concerning as hearing loss can make communication more challenging, which creates a greater reliance on cognitive processes such as thinking and memory to navigate social interactions. This challenge is exacerbated when individuals experience cognitive dysfunction related to chemotherapy, commonly referred to as 'chemo brain'. Addressing these communication difficulties is crucial for promoting healthy ageing and maintaining social engagement. It is expected that cancer patients from the most deprived backgrounds would experience greater hearing loss following chemotherapy than those from less deprived backgrounds.\n\nAs a secondary aim, this study will also investigate how hearing loss may affect cognitive function. Specifically, it will assess whether differences in speech-in-noise performance from pre- to post-treatment predict cognitive performance post-treatment, to understand if changes in hearing over time are associated with changes in cognition. The study will also explore how socioeconomic deprivation, cumulative chemotherapy dose, and treatment duration influence these relationships. By identifying disparities in hearing loss and possible associations with cognition, this research will help guide future hearing screening and intervention strategies for cancer patients.",[244,646,30,647],"Chemo Brain","Hearing",[244,649,30,647],"Chemo brain","2026-04-20",{"date":526,"type":36},{"date":653,"type":23},"2026-05-02",{"date":655,"type":23},"2028-09-01",{"name":657,"class":43},"Lancaster University"]